Jun 03, 2024
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
May 15, 2024
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
May 02, 2024
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Apr 28, 2024
Immutep Quarterly Activities Report Q3 FY24
Apr 23, 2024
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
